Robert M. Plenge - Sep 14, 2021 Form 4 Insider Report for Translate Bio, Inc. (TBIO)

Role
Director
Signature
/s/ Paul D. Burgess, as attorney-in-fact for Robert Plenge, M.D.
Stock symbol
TBIO
Transactions as of
Sep 14, 2021
Transactions value $
$0
Form type
4
Date filed
9/14/2021, 07:28 PM
Previous filing
Jun 16, 2021
Next filing
Jul 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBIO Stock Option (right to buy) Sale $0 -37.8K -100% $0.00* 0 Sep 14, 2021 Common Stock 37.8K $12.36 Direct F1, F2
transaction TBIO Stock Option (right to buy) Sale $0 -18.9K -100% $0.00* 0 Sep 14, 2021 Common Stock 18.9K $10.20 Direct F1, F3
transaction TBIO Stock Option (right to buy) Sale $0 -18.9K -100% $0.00* 0 Sep 14, 2021 Common Stock 18.9K $15.33 Direct F1, F4
transaction TBIO Stock Option (right to buy) Sale $0 -20K -100% $0.00* 0 Sep 14, 2021 Common Stock 20K $20.43 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F2 This option was granted on April 10, 2019. The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on May 10, 2019 and ending on the three year anniversary of April 10, 2019.
F3 This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020.
F4 This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021.
F5 This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant.